{"nctId":"NCT01180634","briefTitle":"MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis","startDateStruct":{"date":"2010-11-04","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":330,"armGroups":[{"label":"Aeroquin 240 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aeroquin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aeroquin","otherNames":["MP-376, Levofloxacin Inhalation solution 240 mg"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (selected):\n\n* \\>/= 12 years of age\n* Confirmed Diagnosis of Cystic Fibrosis\n* Positive sputum culture for P. aeruginosa at screening and within the past 12 months\n* Patients are able to elicit an FEV1 \\>/= 25% but \\</= 85% of predicted value at screening\n* Have received at least 3 courses of inhaled antimicrobials over the preceding 12 months\n* Clinically stable with no changes in health status within the last 28 days\n* Able to reproducibly produce sputum and perform spirometry\n\nExclusion Criteria (selected):\n\n* Use of any nebulized or systemic antibiotics within 28 days prior to baseline\n* History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication\n* Evidence of respiratory infections within 14 days prior to dosing\n* CrCl \\< 20ml/min or \\< 20ml/min/1.73 m2 at Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to an Exacerbation","description":"The start of the exacerbation was determined by the earliest date at which a participant concurrently met at least 4 of the 12 modified Fuchs symptoms/signs; discontinued from the study early; died; or received an antipseudomonal agent for an event that did not meet modified Fuchs criteria but was determined to be an exacerbation by the Blinded Exacerbation.\n\nFuchs symptoms/signs;\n\n* Change in sputum\n* New or increased hemoptysis\n* Increased cough\n* Increased dyspnea\n* Malaise, fatigue or lethargy\n* Temperature above 38oC\n* Anorexia or weight loss\n* Sinus pain or tenderness\n* Change in sinus discharge\n* Change in physical examination of the chest\n* Decrease in pulmonary function by 10 percent or more from a previously recorded value\n* Radiographic changes indicative of pulmonary infection\n\nMedian and 95%Ci were estimated using Kaplan Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"51.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in One Second (FEV1)","description":"FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer. Least squares (LS) mean and standard error are determined from a repeated measures model with terms for treatment, visit, treatment\\*visit, region (US, non-US), age (12-18 years, \\>18 years), and baseline FEV1 (\\<55%, \\>=55%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.638"},{"groupId":"OG001","value":"1.49","spread":"0.531"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pseudomonas Aeruginosa Sputum Density","description":"Pseudomonas aeruginosa density was measured as log10 colony-forming units \\[CFU\\] per gram sputum. LSMean and standard are determined from a repeated measures model with terms for treatment, visit, treatment\\*visit, region (US, non-US), age (12-18 years, \\>18 years), baseline FEV1 (\\<55%, \\>=55%), and baseline organism log density.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.170"},{"groupId":"OG001","value":"-0.59","spread":"0.139"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R)","description":"The Cystic Fibrosis Questionnaire (CFQ-R) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. LSMean and standard error were determined from a repeated measures model with terms for treatment, visit, treatment\\*visit, region (US, non-US), age (12 to 18 years, \\> 18 years), Baseline FEV1 (\\<55%, ≥ 55%), and Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.66","spread":"1.374"},{"groupId":"OG001","value":"4.94","spread":"1.118"}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline in Percent Predicted FEV1","description":"FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer. Least squares (LS) mean and standard error are determined from a repeated measures model with terms for treatment, visit, treatment\\*visit, region (US, non-US), age (12-18 years, \\>18 years), and baseline FEV1 (\\<55%, \\>=55%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"1.041"},{"groupId":"OG001","value":"3.66","spread":"0.866"}]}]}]},{"type":"SECONDARY","title":"Time to Administration of Other Systemic and/or Inhaled Antipseudomonal Antimicrobials","description":"Participants who had at least one of four worsening respiratory symptoms (increased cough, increased sputum/chest congestion, decreased exercise tolerance, decreased appetite) at the time of administration of the anti-pseudomonal antimicrobial agent were included in the analysis. Median and 95% CI are estimated using Kaplan Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Hospitalization","description":"Median and 95%CI was estimated using Kaplan Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events","description":"An AE was defined as any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a Study Drug, whether or not considered related to the Study Drug.\n\nAn AE could potentially be a new disease, any untoward event, or an exacerbation of a pre-existing condition. AEs included, but were not limited to:\n\n* Any symptom not previously reported by the patient (medical history)\n* An exacerbation of a pre-existing illness\n* An increase in frequency or intensity of a pre-existing episodic event or condition\n* A condition first detected or diagnosed after Study Drug administration even though the condition may have been present before the start of the study\n* Overdose of Study Drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":219},"commonTop":["Cough","Nausea","Sputum increased","Respiratory tract congestion","Dysgeusia"]}}}